Article ; Online: Biological therapies for the treatment of psoriasis in pediatrics.
Expert opinion on biological therapy
2023 Volume 23, Issue 12, Page(s) 1219–1226
Abstract: Introduction: Psoriasis is a multifactorial, immune-mediated condition with predominant skin involvement. It may develop at any age. In one-third of patients, the first symptoms of psoriasis start during childhood or adolescence. A marked impairment of ... ...
| Abstract | Introduction: Psoriasis is a multifactorial, immune-mediated condition with predominant skin involvement. It may develop at any age. In one-third of patients, the first symptoms of psoriasis start during childhood or adolescence. A marked impairment of the quality of life of patients and their caregivers is often associated. Areas covered: Databases including PubMed and Clinicaltrials.gov were used to identify clinical studies involving pediatric patients with psoriasis. In the last few years, the implementation of therapy with drugs targeting cytokines like interleukin (IL)-12/23 and IL-17A has expanded the number of available therapeutic options in pediatric psoriasis. This review focuses on the latest evidence on the clinical efficacy and safety profile of drugs licensed for severe pediatric psoriasis. Expert opinion: Increasing knowledge about the pathogenetic mechanisms underlying pediatric psoriasis is leading to an improvement in disease management. Effective treatment is crucial in patients affected with moderate to severe disease to reduce the burden of the disease and avoid stigmatization. The treatment of pediatric psoriasis remains challenging for specific clinical subtypes, when difficult areas are involved, after resistance to multiple treatments, and when psoriatic arthritis is associated. A personalized approach and a thorough understanding of the disease are required to advance pediatric psoriasis care. |
|---|---|
| MeSH term(s) | Humans ; Child ; Quality of Life ; Psoriasis/diagnosis ; Psoriasis/drug therapy ; Arthritis, Psoriatic/drug therapy ; Cytokines/therapeutic use ; Biological Therapy ; Interleukin-23 |
| Chemical Substances | Cytokines ; Interleukin-23 |
| Language | English |
| Publishing date | 2023-12-28 |
| Publishing country | England |
| Document type | Journal Article ; Review |
| ZDB-ID | 2052501-1 |
| ISSN | 1744-7682 ; 1471-2598 |
| ISSN (online) | 1744-7682 |
| ISSN | 1471-2598 |
| DOI | 10.1080/14712598.2023.2281496 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6094: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.